Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises
Proceeds Cover Year 1 eRapa Phase 3 Obligations, Unlocking Twice that Amount in Non-dilutive Grant Funding
Biodexa Pharmaceuticals PLC, (NASDAQ:BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces $7 million of gross proceeds from the exercise of previously issued warrants and an agreement between the Company and several accredited investors to exercise certain existing Series E warrants ("Series E Warrants") and Series F warrants ("Series F Warrants," and together with the Series E Warrants, the "Existing Warrants") to purchase up to an aggregate of 4,358,322 of the Company's American Depositary Shares ("ADSs) (each ADS represents 400 ordinary shares, nominal value £0.001 of the Company ("Ordinary Shares")).
Posted In: BDRX